(Test Bank) Prescriber's Guide Stahl's Essential Psychopharmacology

Stahl, 6

Nursing

Test Bank

6th Edition

• $15.00 $50.00

---

Description

Test Bank for Prescriber's Guide Stahl's Essential Psychopharmacology, The downloadable file consists of 894 pages, and the total size of the file is 27.46 MB. Purchase now only for highly discounted price.

Author(s): Stahl

---

---

Study Note Preview

Stahl’s Essential Psychopharmacology Prescriber’s Guide With the range of psychotropic drugs expanding and the usages of existing medications diversifying, we are pleased to present this very latest edition of what has become the indispensable formulary in psychopharmacology. This new edition features seven new compounds as well as information about several new formulations of existing drugs. In addition, many important new indications are covered for existing drugs, as are updates to the profi les of the entire content and collection, including expansion of the sections on long-acting injectable formulations of antipsychotics. With its easy-to-use, template-driven navigation system, The Prescriber’s Guide combines evidence-based data with clinically informed advice to support everyone prescribing in the fi eld of mental health. Stephen M. Stahl is Adjunct Professor of Psychiatry at the University of California, San Diego, and Honorary Visiting Senior Fellow in Psychiatry at the University of Cambridge, UK. He has conducted various research projects awarded by the National Institute of Mental Health, Veterans Affairs, and the pharmaceutical industry. Author of more than 500 articles and chapters, Dr Stahl is also the author of the bestseller Stahl’s Essential Psychopharmacology . SIXTH EDITION Stahl’s Essential Psychopharmacology Prescriber’s Guide SIXTH EDITION Stephen M. Stahl University of California at San Diego, San Diego, California Editorial assistant Meghan M. Grady With illustrations by Nancy Muntner University Printing House, Cambridge CB2 8BS, United Kingdom One Liberty Plaza, 20th Floor, New York, NY 10006, USA 477 Williamstown Road, Port Melbourne, VIC 3207, Australia 4843/24, 2nd Floor, Ansari Road, Daryaganj, Delhi – 110002, India 79 Anson Road, #06-04/06, Singapore 079906 Cambridge University Press is part of the University of Cambridge. It furthers the University’s mission by disseminating knowledge in the pursuit of education, learning, and research at the highest international levels of excellence. www.cambridge.org Information on this title: www.cambridge.org/9781316618134 © Stephen M. Stahl 2005, 2006, 2009, 2011, 2014, 2017 This publication is in copyright. Subject to statutory exception and to the provisions of relevant collective licensing agreements, no reproduction of any part may take place without the written permission of Cambridge University Press. First published 2005 Revised and updated edition published 2006 Third edition published 2009 Fourth edition published 2011 Fifth edition published 2014 Sixth edition published 2017 Printed in the United Kingdom by Clays, St Ives plc A catalog record for this publication is available from the British Library. ISBN 978-1-316-61813-4 Paperback ISBN 978-1-108-40488-4 Spiral Additional resources for this publication at www.stahlonline.org Every effort has been made in preparing this book to provide accurate and up-to-date information that is in accord with accepted standards and practice at the time of publication. Although case histories are drawn from actual cases, every effort has been made to disguise the identities of the individuals involved. Nevertheless, the authors, editors, and publishers can make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. The authors, editors, and publishers therefore disclaim all liability for direct or consequential damages resulting from the use of material contained in this book. Readers are strongly advised to pay careful attention to information provided by the manufacturer of any drugs or equipment that they plan to use. Cambridge University Press has no responsibility for the persistence or accuracy of URLs for external or third-party Internet Web sites referred to in this publication, and does not guarantee that any content on such Web sites is, or will remain, accurate or appropriate. v Contents Introduction ix List of icons xiii 1 acamprosate 1 2 agomelatine 5 3 alprazolam 11 4 amisulpride 17 5 amitriptyline 25 6 amoxapine 33 7 amphetamine (d) 39 8 amphetamine (d,l) 45 9 aripiprazole 53 10 armodafi nil 65 11 asenapine 71 12 atomoxetine 77 13 benztropine 83 14 blonanserin 87 15 brexpiprazole 93 16 buprenorphine 101 17 bupropion 107 18 buspirone 113 19 caprylidene 117 20 carbamazepine 121 21 cariprazine 127 22 chlordiazepoxide 133 23 chlorpromazine 139 24 citalopram 145 25 clomipramine 151 26 clonazepam 159 27 clonidine 165 28 clorazepate 171 29 clozapine 177 30 cyamemazine 187 31 desipramine 193 32 desvenlafaxine 201 33 dextromethorphan 207 34 diazepam 211 vi 35 diphenhydramine 217 36 disulfi ram 221 37 donepezil 225 38 dothiepin 231 39 doxepin 237 40 duloxetine 245 41 escitalopram 251 42 estazolam 257 43 eszopiclone 261 44 fl ibanserin 265 45 fl umazenil 269 46 fl unitrazepam 273 47 fl uoxetine 277 48 fl upenthixol 283 49 fl uphenazine 289 50 fl urazepam 297 51 fl uvoxamine 301 52 gabapentin 307 53 galantamine 313 54 guanfacine 319 55 haloperidol 323 56 hydroxyzine 331 57 iloperidone 335 58 imipramine 341 59 isocarboxazid 349 60 ketamine 357 61 lamotrigine 361 62 levetiracetam 369 63 levomilnacipran 373 64 lisdexamfetamine 379 65 lithium 385 66 lofepramine 391 67 lofl azeptate 397 68 lorazepam 403 69 lorcaserin 409 70 loxapine 413 71 lurasidone 419 72 maprotiline 427 73 memantine 435 74 mesoridazine 439 vii 75 methylfolate (l) 445 76 methylphenidate (d) 449 77 methylphenidate (d,l) 455 78 mianserin 463 79 midazolam 469 80 milnacipran 473 81 mirtazapine 479 82 moclobemide 485 83 modafi nil 491 84 molindone 497 85 nalmefene 501 86 naltrexone 505 87 naltrexone-bupropion 509 88 nefazodone 513 89 nortriptyline 519 90 olanzapine 527 91 oxazepam 537 92 oxcarbazepine 543 93 paliperidone 549 94 paroxetine 561 95 perospirone 569 96 perphenazine 573 97 phenelzine 579 98 phentermine-topiramate 585 99 pimavanserin 589 100 pimozide 593 101 pipothiazine 599 102 prazosin 605 103 pregabalin 609 104 propranolol 613 105 protriptyline 617 106 quazepam 623 107 quetiapine 627 108 ramelteon 635 109 reboxetine 639 110 risperidone 645 111 rivastigmine 655 112 selegiline 661 113 sertindole 671 114 sertraline 677 viii 115 sodium oxybate 685 116 sulpiride 689 117 suvorexant 695 118 tasimelteon 699 119 temazepam 703 120 thioridazine 707 121 thiothixene 713 122 tiagabine 719 123 tianeptine 725 124 topiramate 729 125 tranylcypromide 735 126 trazodone 741 127 triazolam 747 128 trifl uoperazine 751 129 trihexyphenidyl 757 130 triiodothyronine 761 131 trimipramine 765 132 valproate 773 133 varenicline 781 134 venlafaxine 785 135 vilazodone 791 136 vortioxetine 797 137 zaleplon 803 138 ziprasidone 807 139 zolpidem 815 140 zonisamide 819 141 zopiclone 823 142 zotepine 827 143 zuclopenthixol 833 Index by drug name 839 Index by use 855 Index by class 863 Abbreviations 866 ix Introduction This Guide is intended to complement Stahl’s Essential Psychopharmacology . Stahl’s Essential Psychopharmacology emphasizes mechanisms of action and how psychotro- pic drugs work upon receptors and enzymes in the brain. This Guide gives practical information on how to use these drugs in clinical practice. It would be impossible to include all available information about any drug in a single work, and no attempt is made here to be comprehensive. The purpose of this Guide is instead to integrate the art of clinical practice with the science of psychopharmacology. That means including only essential facts in order to keep things short. Unfortunately that also means excluding less critical facts as well as extraneous information, which may nevertheless be useful to the reader but would make the book too long and dilute the most important information. In deciding what to include and what to omit, the author has drawn upon common sense and 30 years of clinical experience with patients. He has also consulted with many experienced clinicians and analyzed the evidence from controlled clinical trials and regulatory fi lings with government agencies. In order to meet the needs of the clinician and to facilitate future updates of this Guide , the opinions of readers are sincerely solicited. Feedback can be emailed to feedback@neiglobal.com. Specifi cally, are the best and most essential psychotropic drugs included here? Do you fi nd any factual errors? Are there agreements or dis- agreements with any of the opinions expressed here? Are there suggestions for any additional tips or pearls for future editions? Any and all suggestions and comments are welcomed. All of the selected drugs are presented in the same design format in order to facili- tate rapid access to information. Specifi cally, each drug is broken down into fi ve sec- tions, each designated by a unique color background: /L50766 therapeutics, /L50766 side effects, /L50766 dosing and use, /L50766 special populations, and /L50766 the art of psychopharmacology, followed by key references. Therapeutics covers the brand names in major countries; the class of drug; what it is commonly prescribed and approved for by the United States Food and Drug Administration (FDA); how the drug works; how long it takes to work; what to do if it works or if it doesn’t work; the best augmenting combinations for partial response or treatment resistance; and the tests (if any) that are required. Side effects explains how the drug causes side effects; gives a list of notable, life- threatening, or dangerous side effects; gives a specifi c rating for weight gain or seda- tion; and gives advice about how to handle side effects, including best augmenting agents for side effects. Dosing and use gives the usual dosing range; dosage forms; how to dose and dosing tips; symptoms of overdose; long-term use; if habit forming, how to stop; pharmaco-kinetics; drug interactions; when not to use; and other warnings or precautions. Special populations gives specifi c information about any possible renal, hepatic, and cardiac impairments, and any precautions to be taken for treating the elderly, children, adolescents, and pregnant and breast-feeding women. The art of psychopharmacology gives the author’s opinions on issues such as the potential advantages and disadvantages of any one drug, the primary target symp-toms, and clinical pearls to get the best out of a drug. x In addition, drugs for which switching between medications can be complicated have a special section called The Art of Switching, which includes clinical pearls and graphical representations to help guide the switching process. There is a list of icons used in this Guide following this Introduction and at the back of the Guide are several indices. The fi rst is an index by drug name, giving both generic names (uncapitalized) and trade names (capitalized and followed by the generic name in parentheses). The second is an index of common uses for the generic drugs included in the Guide and is organized by disorder/symptom. Agents that are approved by the FDA for a particular use are shown in bold. The third index is organized by drug class and lists all the agents that fall within each par-ticular class. In addition to these indices there is a list of abbreviations. Readers are encouraged to consult standard references 1 and comprehensive psy- chiatry and pharmacology textbooks for more in-depth information. They are also reminded that the art of psychopharmacology section is the author’s opinion. It is strongly advised that readers familiarize themselves with the standard use of these drugs before attempting any of the more exotic uses discussed, such as unusu-al drug combinations and doses. Reading about both drugs before augmenting one with the other is also strongly recommended. Today’s psychopharmacologist should also regularly track blood pressure, weight, and body mass index for most of his or her patients. The dutiful clinician will also check out the drug interactions of non-central nervous system (CNS) drugs with those that act in the CNS, including any prescribed by other clinicians. Certain drugs may be for experts only and might include clozapine, thioridazine, pimozide, nefazodone, mesoridazine, and monoamine oxidase (MAO) inhibitors, among others. Off-label uses not approved by the FDA and inadequately studied doses or combinations of drugs may also be for the expert only, who can weigh risks and benefi ts in the presence of sometimes vague and confl icting evidence. Pregnant or nursing women, or people with two or more psychiatric illnesses, substance abuse, and/or a concomitant medical illness may be suitable patients for the expert only. Controlled substances also require expertise. Use your best judgment as to your level of expertise and realize that we are all learning in this rapidly advancing fi eld. The practice of medicine is often not so much a science as it is an art. It is important to stay within the standards of medical care for the fi eld, and also within your personal comfort zone, while trying to help extremely ill and often diffi cult patients with medicines that can sometimes transform their lives and relieve their suffering. Finally, this book is intended to be genuinely helpful for practitioners of psychophar- macology by providing them with the mixture of facts and opinions selected by the author. Ultimately, prescribing choices are the reader’s responsibility. Every effort has been made in preparing this book to provide accurate and up-to-date information in accord with accepted standards and practice at the time of publication. Neverthe-less, the psychopharmacology fi eld is evolving rapidly and the author and publisher make no warranties that the information contained herein is totally free from error, not least because clinical standards are constantly changing through research and regulation. Furthermore, the author and publisher disclaim any responsibility for the 1 For example, Physician’s Desk Reference and Martindale: The Complete Drug Reference. xicontinued currency of this information and disclaim all liability for any and all dam- ages, including direct or consequential damages, resulting from the use of informa-tion contained in this book. Doctors recommending and patients using these drugs are strongly advised to pay careful attention to, and consult information provided by, the manufacturer. xiii List of icons alcohol dependence treatment alpha adrenergic blocker alpha 2 agonist anticonvulsant antihistamine antiparkinson/anticholinergic benzodiazepine beta blocker cholinesterase inhibitor conventional antipsychotic dopamine stabilizer fl ibanserin lithium lorcaserin medical food